While the newest generation of insulins promise to provide more physiological control of blood sugars, many patients using these insulins have inadequately controlled diabetes. Newer biosimilars and generic versions for long-acting and ultra-short acting insulins are coming onto the market, their prices remain high compared to NPH and Regular insulins, and 70/30 mixes of NPH and Regular. Choosing an optimal, nuanced approach, while being mindful of comparative costs, can be challenging. It requires the entire care team to work together from a common knowledge base. PHC sponsored a series of webinars to help update teams in using optimally using insulin in challenging clinical scenarios. Presented by Dr. Jay Shubrook, a professor at Touro University School of Medicine, and an expert in teaching about optimal diabetes care.
NOTE: The materials used in these past presentations do include information specific to PHC's 2021 Pharmacy Formulary. The PHC Pharmacy Formulary no longer applies to the pharmacy benefit: As of January 1, 2022, the pharmacy benefit is only through Medi-Cal Rx (Magellan Medicaid Administration, Inc.).
Go to Medi-Cal Rx for the Medi-Cal Covered Drug List (2022 Pharmacy Benefit).
